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Abstract
Pentose phosphate pathway (PPP) is a major glucose metabolism pathway, which has a fundamental role in cancer
growth and metastasis. Even though PPP blockade has been pointed out as a very promising strategy against cancer,
effective anti-PPP agents are not still available in the clinical setting. Here we demonstrate that the natural molecule
polydatin inhibits glucose-6-phosphate dehydrogenase (G6PD), the key enzyme of PPP. Polydatin blocks G6PD causing
accumulation of reactive oxygen species and strong increase of endoplasmic reticulum stress. These effects are
followed by cell cycle block in S phase, an about 50% of apoptosis, and 60% inhibition of invasion in vitro. Accordingly,
in an orthotopic metastatic model of tongue cancer, 100 mg/kg polydatin induced an about 30% tumor size reduction
with an about 80% inhibition of lymph node metastases and 50% reduction of lymph node size (p < 0.005). Polydatin
is not toxic in animals up to a dose of 200 mg/kg and a phase II clinical trial shows that it is also well tolerated in
humans (40 mg twice a day for 90 days). Thus, polydatin may be used as a reliable tool to limit human cancer growth
and metastatic spread.
Introduction
The pentose phosphate pathway (PPP) has recently been
shown to have a crucial role in cancer cell growth by pro-
viding both nucleotide precursors, needed for proliferation,
and NADPH used for both intracellular ROS detoxiﬁcation
and catabolic metabolism1–5. The inhibition of PPP key
enzymes, including glucose-6-phosphate dehydrogenase
(G6PD), strongly affects cancer cell proliferation in vitro, as
well as in vivo6, 7. G6PD is upregulated in many human
cancers and correlates with poor prognosis8–12, whereas
cancer patients harboring G6PD mutation show longer
survival and reduced metastases13–15. Moreover, G6PD
activity can be regulated by oncogenes such as PI3k/AKT,
Ras, Src, mTORC1, or by oncosuppressors such as p53 and
TAp734. Interestingly, the inhibition of G6PD may restore
sensitivity of cancer cells to chemotherapy16. Therefore,
PPP inhibition has been proposed as an attractive ther-
apeutic strategy against cancer17. However, the inhibition of
G6PD in clinical settings is hampered by the lack of speciﬁc
inhibitors. To our knowledge, the only G6PD inhibitor
ever used in vivo is the dehydropiandrosterone (DHEA),
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an endogenous steroid hormone, which is produced by
adrenal glands acting as a metabolic precursor of andro-
gen and estrogen. DHEA is rapidly converted into steroid
hormones in vivo and its efﬁcacy as an inhibitor of G6PD
is under dispute18.
Polydatin (3,4′,5-trihydroxystilbene-3-β-d-glucoside; trans-
resveratrol 3-β-mono-D-glucoside; piceid) is a natural
molecule found in Polygonum cuspidatum and other plants.
Polydatin is a glucoside of resveratrol and, together with
other polyphenols, has been shown to have several biological
effects, including the induction of apoptosis in carcinoma
cells19–22. Here we have studied the effects of polydatin on
G6PD activity, ROS levels, ER stress, and programmed cell
death, and its role in inhibiting cancer cell proliferation and
invasion both in vitro and in vivo.
Results
Polydatin inhibits cancer cell proliferation and cell cycle
progression
We assessed the viability of head and neck squamous
cell carcinoma (HNSCC) cell lines after polydatin treat-
ments at different concentrations (from 2 to 100 µM at 24
or 48 h), by MTT assay. We found that polydatin-reduced
cell viability in a dose- and time-dependent manner at an
EC50 of 22 µM for 24 h and 17 µM for 48 h, respectively
(Fig. 1a). Based on these data we have selected, for all the
subsequent experiments, concentrations of 10, 20, and 30
µM that represent the EC25, EC50, and EC75. To conﬁrm
the effects on cell viability, we performed an apoptosis
assay based on Annexin V/PI staining (Fig. 1b and S1A).
We observed a dose- and time-dependent reduction of cell
viability and an increased apoptosis and necrosis of treated
cells. Polydatin affect, as well the cell cycle inducing a
block in the S phase that reﬂected the ability of polydatin
to inhibit cell proliferation (Fig. 1c and Fig. S1B). These
results demonstrate that polydatin reduces viability,
increases apoptosis, and prevents cell cycle progression of
primary HNSCC cells. Similar results were obtained on
breast cancer MCF7 cell line (Fig. S2D-F).
Polydatin induces ER stress-driven cell death
To understand the molecular mechanism leading to
cell death, we hypothesized that polydatin could cause
endoplasmic reticulum (ER) stress, which in turn can
lead to apoptosis. We performed an immunoﬂuorescence
staining (IF) using the vital dye ER-Tracker, which accu-
mulate into ER. As a positive control, we used tunica-
mycin, a known inducer of ER stress. Following
treatment with either tunicamycin or different con-
centrations of polydatin, we observed an increased ﬂuor-
escence, which corresponds to an enlarged ER (Fig. 1d).
Inositol-requiring enzyme 1 (IRE1) is an enzyme with
intrinsic kinase and endoribonuclease activity that is
activated during ER stress. After oligomerization and
auto-phosphorylation, IRE1 acts on X-box binding pro-
tein 1 (XBP1) mRNA and causes an unconventional
alternative splicing that activates XBP1 transcription fac-
tor to upregulate ER chaperones. Clusters of oligomer-
ization of phospho-IRE1 were observed in both polydatin
and tunicamycin-treated cells by both IF (Fig. 1e) and
immunoblotting (Fig. 1f). Moreover, a signiﬁcant increase
of XBP1 mRNA and its spliced form (sXBP1 mRNA) was
observed. This effect was dose- and time-dependent and
began 4 h following treatment (Fig. 1f). Following ER
stress, both IRE1 and PERK (protein kinase RNA-like ER
kinase) induce the transcription of CCAAT-enhancer-
binding protein homologous protein (CHOP), which is
involved in the activation of apoptosis. As expected, the
phosphorylated form of PERK and two of its downstream
effectors p-eIF2α and ATF4 increased after polydatin
treatment (Fig. 1g). Finally, CHOP transcript and protein
also increased in response to polydatin treatment in a
dose- and time-dependent manner as early as 2 h after
treatment (Fig. 1f, g). ER chaperons such as BiP and CRT
increased after treatment too, while CNX did not show
signiﬁcant changes upon treatment. To understand whe-
ther ER stress was driving cell death, we showed that the
block of IRE1 or PERK activation, by speciﬁc inhibitors or
by knockdown, partially reverted polydatin-induced
cytotoxicity (Fig. 2a).
Polydatin inhibits G6PD and induces oxidative and ER
stresses
To additionally investigate the molecular mechanism of
action of polydatin, we performed a mass spectrometry
protein expression analysis of cell lysates from untreated
and polydatin-treated cells (Fig. S2A and S2B) that was
compared with one from tunicamycin-treated cells. As
expected, the expression of proteins involved in ER stress
was affected by tunicamycin treatment (Table S1).
Polydatin-treated cells also showed a pattern of expres-
sion that was consistent with stress response and which
overlapped that one of tunicamycin-treated cells. Among
the proteins modulated by polydatin, we found a group
of proteins belonging to the family of oxidoreductases
and that were not altered in tunicamycin-treated cells
(Fig. S2B and Table S1). Speciﬁcally, we found that
seven oxidoreductases, including isocitrate dehydrogenase
1 (IDH1), G6PD and 6-phosphogluconate-dehydrogenase
(6PGD), were signiﬁcantly upregulated in polydatin trea-
ted samples (24 h treatment). G6PD and 6PGD are both
part of PPP and together with IDH1 are responsible for
the production of almost all the cytosolic NADPH, which
is necessary for redox balance. Indeed, we found a sig-
niﬁcant reactive oxygen species (ROS) accumulation fol-
lowing polydatin treatment (Fig. 2b, S5). ROS plays a
critical role in many cellular processes and can be pro-
duced in the cytosol and in several organelles, including
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ER and mitochondria. To determine the role of ROS
accumulation in ER stress, we incubate the cells with the
antioxidant N-acetylcysteine (NAC), prior to polydatin
treatment. Pre-treatments with NAC completely abro-
gated ER stress induced by polydatin, suggesting a cau-
sative link between oxidative and ER stress (Fig. 2c).
As G6PD is the PPP limiting enzyme, its inhibition
would affect NADPH production, and results in redox
imbalance. Thus, we hypothesized that the biological
effects observed could be a consequence of G6PD block.
Therefore, we performed a G6PD enzyme activity assay
on carcinoma protein lysates, as well as on puriﬁed G6PD.
In both cases, polydatin-inhibited G6PD activity in a
concentration-dependent manner (Fig. 2d, S2C). This was
paralleled by an increase of the NADP+ /NADPH ratio in
a time-dependent manner (Fig. 2e). These results suggest
that polydatin inhibits G6PD causing an imbalance in
NADP+ /NADPH ratio that leads to an increase of oxi-
dative stress. The capacity of tumor cells to control oxi-
dative stress through NADPH production is directly
correlated with their ability to migrate. Indeed, in vitro
invasion assays conﬁrmed that polydatin-inhibited cancer
cell invasion in a dose-dependent manner (Fig. 2f).
G6PD overexpression counteracts polydatin antitumor
effects
To conﬁrm that G6PD inhibition was functionally
related to the biological effects induced by polydatin, we
Fig. 1 Effects of polydatin treatment on UMSCC103. a Viability assay measured by MTT (concentration range 0–70 µM) at 24 and 48 h
posttreatment. b Analysis of apoptosis by Annexin V/PI assay at 24 and 48 h posttreatment (for original dot plots see Fig. S1A). c Cell cycle analysis (for
original histograms and analyses see Fig. S1B). d IF with ER-Tracker 24 h posttreatment; tunicamycin is used as positive control. e Immunoblot for
phospho-IRE1, 24 h posttreatment, polydatin treatments 10–30 μM. IF for phospho-IRE1, 24 h posttreatment; tunicamycin is used as positive control;
red arrows represent phospho-IRE cluster. f Quantitative real time PCR for CHOP and spliced XBP1. g Immunoblot for UPR pathway and ER chaperons,
24 h posttreatment, Polydatin 20 μM. *p < 0.05. N= 3, error bar= 95% conﬁdence
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generated a G6PD overexpressing cell line (MCF7G6PD+)
(Fig. S3A). MCF7G6PD+ were resistant to polydatin
treatment in both viability assay and apoptosis analyses.
Indeed, 70 µM polydatin at 24 h cause a 50% reduction in
viability in mock cells vs 35% in MCF7G6PD+. Moreover,
35 µM polydatin at 48 h caused 65% mortality in mock vs
40% in MCF7G6PD+ (Fig. S3B). Polydatin treatment
caused a strong and signiﬁcant increase of the S phase of
cell cycle at 17.5 µM (16 ± 5% to 63 ± 10%), while it
increased both S and G1 phase at the expense of G2/M at
35 and 70 μM in mock-transfected cells at 48 h. Analysis
of cell cycle at 48 h showed always an increase of S and
G2/M phases. On the other hand, the MCF7G6PD+ cell
cycle, was much less perturbed by polydatin that induced
only a small increase of S phase at a concentration of 35
µM at 48 h (from 20 ± 5% to 48 ± 6%) (Fig. S3C).
MCF7G6PD+ cells were resistant to ER stress induced by
polydatin as showed by ER-Tracker staining (Fig. S3D).
On the other hand, tunicamycin induced a strong ER
stress in both mock and MCF7G6PD+ cells. This result
suggests that MCF7G6PD+ are not resistant to ER stress
induced by mechanisms independent from redox imbal-
ance. To further conﬁrm this, we show that CHOP and
spliced-XBP1 transcripts were signiﬁcantly higher in
polydatin-treated mock cells than MCF7G6PD+ (Fig. 3b).
The phosphorylation and clustering of IRE1 was strong
and evident in mock cells but completely undetectable in
MCF7G6PD+ (Fig. S3D). Analysis of redox status after
Fig. 2 Polydatin Inhibits G6PD causing redox imbalance, which leads to ER stress and cell death. a Viability assay (MTT) of UMSCC103 treated
with polydatin (20 µM) and 4μ8c (IRE inhibitor), GSK2606414 (PERK inhibitor) or with siRNA for either IRE1 or PERK, 24 or 48 h posttreatment,
respectively. b IF with CellROX (for oxidative stress determination), 24 h posttreatment (In ﬁg S5: menadione is used as positive control; N-acetylcysteine
(NAC) is used as ROS scavenger; quantitative assay). c IF with ER-Tracker on UMSCC103 treated with polydatin in combination with NAC, 24 h
posttreatment. d G6PD enzymatic assay on UMSCC103 cell lysates (the same assay performed with puriﬁed enzyme is found in Fig. S2C). e NADP
+ /NADPH ratio on polydatin-treated cells. f Invasion assay of UMSCC103 after polydatin treatment. *p < 0.05, N= 3, error bar= 95% conﬁdence
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polydatin treatment revealed an about two-fold increase
of ROS accumulation in mock cells at concentration
above 17.5 µM (Fig. S3D) but no effect in MCF7G6PD+.
Again, invasion ability of MCF7G6PD+ was in the same
way much less inhibited by polydatin treatment if com-
pared to mock cells (Fig. S3E).
Polydatin prevents lymph node metastases in an
experimental orthotopic model of cancer
Polydatin-induced cancer cell death and blocked inva-
sion in vitro. Therefore, we developed an orthotopic
metastatic model of oral cancer by injecting UMSCC103
in mice tongues, assessing the timing of tumor growth
and lymph node metastases occurrence. Primary tumors
were examined at the end of the experiment when mice
were killed, while lymph node metastases were followed
using ultrasound imaging. Primary tumor growth was
determined by weighting entire tongues and showed sta-
tistically signiﬁcant differences between polydatin-treated
and -untreated mice (Fig. 4a). The reduction of primary
tumors’ growth was ≤30%. The squamous cell carcinoma
nature of the implanted tumor was conﬁrmed by an
expert pathologist (Fig. 4a). Ultrasound imaging and size
determination of cervical lymph nodes revealed a much
greater effect of polydatin on metastases (Fig. 4c, d). In
details, the average size of untreated mice lymph nodes
was 5 ± 0.5 mm2 vs 3 ± 0.3 mm2 (p < 0.005) for the treated
ones. These data were conﬁrmed after mice killing and
Fig. 3 Generation of G6PD overexpressing cell lines. Differences with mock transfection after polydatin treatment. a Viability assay (MTT) in
G6PD+ and mock-transfected cells following polydatin treatment. b Quantitative real time PCR on G6PD+ and mock-transfected cells for CHOP and
spliced XBP1 after polydatin treatment. c IF with ER-Tracker on G6PD+ and mock-transfected cells after polydatin treatment. d Flow cytometry of
CellRox (oxidative stress determination) on G6PD+ and mock-transfected cells following polydatin treatment. e Invasion assay in G6PD+ and mock-
transfected cells. *p < 0.05, N= 3, error bar= 95% conﬁdence
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Fig. 4 Analysis of tumor growth and lymph node invasion in an orthotopic xenograft model. a H&E staining of orthotopic xenograft in the
tongue; bars, tongue weight of treated and untreated mice. b H&E staining of lymph node metastases. c Lymph node sonography and size
determination on treated, untreated and control (no tumor) mice. Insets on the right, enlarged images. d Plot of lymph node size determined by
sonography. e Lymph node weights of treated and untreated mice. f, g Analysis of combination index (CI) with compusin software for the
combination polydatin/cisplatin and polydatin/afatinib. *p < 0.05, N= 3, error bar= 95% conﬁdence
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when lymph nodes were removed, weighted, and exam-
ined by a pathologist. We were able to identify and
remove about 5/6 cervical lymph nodes per mouse.
Indeed, the average weight of untreated mice was 6.2 ±
0.3 mg vs 2.9 ± 0.1 mg for the treated ones (p < 0.005)
(Fig. 4e). All lymph nodes were then examined for
metastases and we found that only two of the treated mice
(out of ten) had lymph node metastases, while eight out of
ten were observed in untreated ones.
G6PD inhibition increase the effect of chemotherapy
PPP has been suggested to be involved in drug resis-
tance in both solid tumors and leukemia. Two major work
of Gregory et al.23 and Catanzaro et al.16 describe an
involvement of G6PD in the resistance to cisplatin
and tyrosine kinase inhibitor. For this reason, we per-
formed analysis of synergism for the combination of
cisplatin/polydatin and afatinib/polydatin. Both combi-
nations were highly synergic at all the concentration used
(Fig. 4f, g; S4).
Discussion
In the present manuscript, we have studied the effect of
polydatin on cancer cells elucidating its biochemical
mechanism of action and biological effects. Based upon
our results, we provide evidence showing that polydatin
induces a potent cancer cell growth inhibition paralleled
by a strong reduction of invasive properties of cancer cells
in vitro and in vivo. The latter effect was reported for the
ﬁrst time and represents a major goal of cancer research,
as cancer metastases control is an unmet need in cancer
treatment. We demonstrate that polydatin directly inhi-
bits G6PD, the limiting enzyme of PPP, causing redox
imbalance, which results in ER stress, cell cycle arrest,
and apoptosis. To elucidate the molecular mechanism of
polydatin, we performed a quantitative proteomic analysis
of lysates from polydatin-treated cells at multiple time
points, and compared the protein expression proﬁles with
tunicamycin-treated cells. This approach enabled the
identiﬁcation of a group of enzymes that signiﬁcantly
increased following the treatment with polydatin but not
with tunicamycin. The enzymes belonged to the family of
oxidoreductases and among these, three enzymes drew
our attention: IDH1, G6PD, and 6PGD. These three
enzymes are involved in glucose metabolism and account
for the production of most of the NADPH. The latter has
been proposed as rate limiting for cell proliferation24–26.
Moreover, NADPH has been demonstrated to be funda-
mental for cancer growth and metastases27, 28. Indeed, we
found that polydatin inhibited G6PD in either a cell lysate
or using the puriﬁed enzyme. To demonstrate that the
cytotoxic effects of polydatin were mediated by G6PD
inhibition, we generated a cell line overexpressing G6PD.
In these cells, treatment with polydatin resulted in a much
lower effect if compared to control cells. This was
observed for all the biological parameters, we analyzed.
G6PD inhibition blocks proliferation and reduces DNA
synthesis29, an effect similar to that one observed when
cancer cells are treated with polydatin that inhibits cell
cycle at the S phase30. In addition, the accumulation of
cells in S phase of cell cycle at the expenses of G2/M is
consistent with nucleotides shortage31. It has to be high-
lighted that, although polydatin has been used for more
than 30 years, the molecular mechanism responsible
for the effects reported have never been elucidated. We
showed, for the ﬁrst time, that the biological effects pro-
duced by polydatin treatment depend on G6PD inhibition
and PPP block. This is, in our opinion, a pivotal ﬁnding, as
speciﬁc G6PD or PPP inhibitors are not currently avail-
able in clinical setting. Indeed, although the PPP has been
identiﬁed as a target for cancer therapy4, 7, 9, 17, 24 and
recently pointed out to be responsible for drug resistance
in humans by a relevant study of Gregory et al.23, the lack
of speciﬁc inhibitors hampers research and clinical
application that aim to target this pathway. The widely
used G6PD inhibitor DHEA is rapidly converted in vivo
into other hormones, which makes this drug not active18.
The inhibitory effect recorded in some clinical trials
seems to be more luckily produced by the interaction
between DHEA and estrogen receptors. Moreover, the
results obtained with DHEA in vitro need to be inter-
preted very carefully due to potential biasing by the sev-
eral biological effects of this hormone. Interestingly, the
capacity of tumor cells to control oxidative stress through
NADPH production is directly correlated with their
ability to form metastases in vivo32. Moreover, Richardson
et al.33, used breast epithelial MCF10A cells (the parental
and benign MCF10A, premalignant MCF10AT, and
malignant MCF10CA1a) and showed that PPP ﬂux
increases with malignancy and correlates with tumor
aggressiveness33. Consistently, the PPP is associated with
invasiveness and seems to play a crucial role during the
metastatic process by protecting metastatic cells5, 34.
Therefore, our ﬁndings demonstrate that polydatin inhi-
bits cancer cell invasion through PPP-dependent NADPH
decrease. On the bases of these ﬁndings, we developed an
orthotopic and metastatic model of oral cancer showing
that polydatin strongly reduced both tumor growth and
lymph node metastases. Interestingly, polydatin has pre-
viously been administered in different animal models to a
dose up to 200 mg/kg with no reported major cardiovas-
cular, hepatic, bone marrow, and renal toxicities35–37.
Pharmacokinetic studies showed that polydatin is absor-
bed and distributed to tissues if given intravenously or by
oral administration38. Phase II clinical trials have been
performed using polydatin at 20–40mg twice a day for a
period, as long as 3 months and none of those reported
any major cardiovascular, hepatic, bone marrow, and
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renal toxic effects39, 40. We showed that the combination
of polydatin with either cisplatin or afatinib is strongly
synergic in inducing cytotoxicity on cancer cells. These
results strongly suggest the use of polydatin in clinical
trials in combination with other antitumor agents in
integrated anticancer strategies.
In conclusion, we show that polydatin reduces tumor
growth and strongly inhibits lymph node metastases in
oral cancer in vivo models with no toxicity. This effect has
to be correlated with the direct inhibition of G6PD, the
limiting enzyme of the PPP. This causes an impairment of
NADPH production, causing ROS-mediated ER stress,
apoptosis, and invasion inhibition (Fig. 5).
Methods
Chemicals, cell culture, and in vitro treatment
All chemicals were purchased from Sigma-Aldrich (St.
Louis, USA) unless otherwise speciﬁed. Trans-polydatin,
with a purity grade higher than 99%, was been supplied
by Ghimas spa (Casalecchio, Bologna, Italy). Selective
inhibitors of IRE1α (4μ8C) and PERK (GSK2606414)
were obtained from Tocris Bioscience (Bristol, United
Kingdom). Afatinib (BIBW2992) was obtained from
Boehringer Ingelheim (Milano, Italy). UMSCC103 (OSCC
cell line) used in this study were established at the
University of Michigan under a protocol approved by
the Institutional Review Board Ofﬁce in accordance with
the university’s regulations and described here41. MCF7
cells were purchased from ATCC. Cells were cultured
in DMEM (Gibco, NY, USA) supplemented with 2mM
glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin
(Invitrogen, Carlsbad, CA), and 10% heat-inactivated fetal
bovine serum (FBS) (Gibco, NY, USA) at 37 °C in a humi-
diﬁed atmosphere under 5% CO2. All cell lines were
kept mycoplasma free, checking was performed every
3 months.
Fig. 5 Schematic representation of Polydatin action on cancer cells
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Invasion assay
The invasion assays were performed using a BD BioCoat
Matrigel Invasion Chamber and BD control inserts
(Becton-Dickinson, USA). The cells, exposed for 24 h to
DMEM alone and with different concentrations of poly-
datin, were resuspended in serum-free DMEM and then
added onto inserts with uncoated ﬁlters (control inserts)
or onto inserts with Matrigel coated ﬁlters (invasion
chambers) at the density of 5 × 104 viable cells/insert.
DMEM containing 10% FBS was used as the chemoat-
tractant. Non-invading cells on the upper side of the
membrane, after incubation for 18 h at 37 °C, 5% CO2,
were removed with cotton swabs and the invading cells
were ﬁxed using methanol and stained with hematoxylin.
Cells that invaded were counted at ×200 magniﬁcation.
Each assay was performed in triplicate. Cells that invaded
the Matrigel insert was compared to the number of cells
that migrate in the control insert, calculating as percen-
tage of invasion42.
RNA isolation and qRT-PCR
Total RNA was isolated by RNeasy Mini Kit (Qiagen)
according to manufacturer’s instructions, RNA was trea-
ted with DNase (Promega, Milan, Italy) to exclude DNA
contamination and 1 μg total RNA reverse-transcribed
using VILO SuperScript (Invitrogen, Monza, Italy). Gene
expression assays were performed on a StepOne Ther-
mocycler (Applied Biosystems, Monza, Italy) and the
ampliﬁcations carried out using SYBR Green PCR Master
Mix (Applied Biosystems, Monza, Italy). The reaction
conditions were as follows: 95 °C for 15min, followed by
40 cycles of three steps consisting of denaturation at 94 °C
for 15 s, primer annealing at 60 °C for 30 s, and primer
extension at 72 °C for 30 s. A melting curve analysis was
performed from 70 °C to 95 °C in 0.3 °C intervals. Each
sample was performed in triplicate. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used to nor-
malize for differences in RNA input. qRT-PCR primer
sequences are given in Supplementary Table 2.
G6PD assay and NADP+/NADPH quantiﬁcation
G6PDH activity was measured by Glucose 6 Phosphate
Dehydrogenase Assay Colorimetric Kit (Abcam, Cam-
bridge, UK). UMSCC103 cells untreated or treated with
polydatin were homogenized in cold PBS, followed by
centrifugation at 8000 × g for 10 min to remove insoluble
materials. G6PDH activity was determined by analysis of
G6PDH-dependent oxidation of glucose-6-phospate,
which leads to the conversion of a nearly colorless probe
to an intensely colored product with an absorbance at 450
nm. All assays were performed at 37 °C. NADP+/NADPH
ratios in cell lines treated with PD were measured
according to the protocol of NADP+/NADPH Quantiﬁ-
cation Kit (MAK038, Sigma). According to the NADPH
standards, the concentration of NADPtotal or NADPH
can be expressed in pmole per 106 cells. The ratio
of NADP+/NADPH was calculated by ((NADPtotal)–
(NADPH)/(NADPH)).
Cell viability assay
Cell viability was measured by the colorimetric 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Cells were seeded in 96-well plates at a
density of 104 cells per well, then they were treated with
100 μL of 1 mg/mL MTT (Sigma) in DMEM medium
containing 10% FBS for 4 h at 37 °C. The medium was
then replaced with 200 μL of DMSO and shaken for
15min, then absorbance at 540 nm was measured using a
microplate ELISA reader with DMSO used as the blank.
To quantify the synergistic or antagonist effect of the
drugs combinations, CompuSyn software was used43.
IF staining
After 24 h treatment with PD at various concentrations,
cells were washed in PBS and ﬁxed with 4% paraf-
ormaldehyde solution and permeabilized with 0.1% Triton
X/PBS solution, then was performed a blocking in 1%
BSA for 1 h at RT. Cells were incubated with anti-pIRE
(Abcam, Cambridge, UK) in PBS for 30 min. Secondary
antibodies were added after a PBS wash in the same
conditions. Cells were incubated in a 1:500 solution of 10
mg/mL Hoechst (Invitrogen) in PBS for 10 min in the
dark. To stain ER cells were incubated with 200 nM ER-
Tracker Blue-White DPX in PBS solution for 20 min
at 37°C. For positive control cells were exposed for 16 h to
5 μg/mL tunicamycin. Images were collected under a
ﬂuorescence microscope (EVOS FL Cell Imaging System,
Thermo Scientiﬁc, Rockford, USA).
CellROX assay
Cells were plated on glass bottom 35-mm MatTek
dishes and treated with PD for 24 h or 100 μMmenadione
for 1 h at 37 °C. A quantity of 50 μM N-acetylcysteine was
added menadione-treated wells. The cells were then
stained with 5 μM CellROX green reagent by adding the
probe to the complete media and incubating at 37 °C for
30min. The cells were then washed with PBS and then
imaged on a ﬂuorescence microscope EVOS FL Cell
Imaging System (Thermo Scientiﬁc, Rockford, USA). N-
acetylcysteine treatment inhibited the ﬂuorescent signal
induced by menadione, conﬁrming that the signal was
speciﬁcally produced by ROS increase44, 45.
FACS analysis
Apoptosis (Annexin V apoptosis detection kit, BD
biosciences), CellROX assay (Thermo Fisher Scientiﬁc,
USA), were performed according to the manufacturer’s
instructions. Cells were analyzed with a FACSAria III
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(BD Biosciences, San Jose, CA) or a BD Accuri Cytometer
(BD Biosciences, San Jose, CA). Data were analyzed by
FlowJo V10 software (FlowJo LLC, USA). For cell cycle
analysis, cells were detached from the plates by trypsini-
zation and then ﬁxed with ice-cold 80% ethanol. The cells
were centrifuged and then stained with a solution of 50
µg/mL propidium iodide and 80 µg/mL RNase A for 60
min at 4 °C in the dark. DNA content and cell cycle dis-
tribution were measured with a FACSARIA III or BD
Accuri Cytometer, data were analyzed using Mod-Fit
software (Verity Software House, USA).
G6PD overexpression
p3-G6PD-t1 and negative control pCMV3-untagged-
NCV (control) hygroycin-resistant plasmids were pur-
chased from Sino Biological Inc. (Sino Biological, Beijing,
China). MCF7 cells were stably transfected with Lipo-
fectamine 3000 (Thermo Fisher Scientiﬁc, Waltham, MA
USA) according to the manufacturer’s instructions. Clones
with upregulated expression of G6PD were selected with
100 µg/mL Hygromycin. Clones were screened by western
blot.
IRE1 and PERK downregulation
UMSCC103 cells were transfected with siRNAs
targeting IRE1 (SASI_Hs01_00194923, Sigma), PERK
(SASI_Hs0100096844, Sigma) or a control siRNA
(SIC001, Sigma) using Lipofectamine 3000 (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) by following the
manufacturer’s instructions.
Protein extraction and western blotting
Cells were lysed in 1X RIPA buffer (150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris-HCl pH 7.5) plus 1% protease inhibitor cocktail, 1%
PMSF (200mM) and 1% sodium orthovanadate (Santa
Cruz Biotechnology, USA). Lysates were clariﬁed by
centrifugation at 8000×g for 5 min at 4°C and equal
amounts of protein were fractionated by SDS-PAGE and
subsequently transferred onto nitrocellulose membrane,
immunoblots were visualized using Supersignal® West
Pico Chemiluminescent substrate (Thermo Scientiﬁc,
Rockford, USA). Proteins were detected with anti-Glucose
6 Phosphate Dehydrogenase (Novus Biologicals, USA);
anti-PERK (phospho T981) (#1055, Elabscience, Huston,
USA); anti-PERK (#3667, Elabscience, Huston, USA);
anti-IRE1 (phospho S724) (ab48187, Abcam, Cambridge,
UK); anti-IRE1 (ab ab37073, Abcam, Cambridge, UK);
Anti-eIF2α (phosphor S51) (9721, Cell Signaling, USA);
anti-α-Tubulin Antibody (#2144 Cell Signalling Tech-
nology, UK); Anti-Calreticulin (ab2907, Abcam, Cam-
bridge, UK); Anti-Calnexin (ab22595, Abcam, Cambridge,
UK); Anti-BiP (BD610978, BD Biosciences, San Jose, CA);
Anti-ATF4 (sc-200, Santa Cruz, Dallas, USA); Anti-Chop
(sc7351, Santa Cruz, Dallas, USA); Anti-XBP1 (ab198999,
Abcam, Cambridge, UK) and Anti-GAPDH (ab9485,
Abcam, Cambridge, UK) were used for assessing loading.
Mass spectrometry
Samples (~50 µg protein) were reduced, alkylated, and
prepared as previously described46. Samples (3 µL, ~ 5 µg
protein digest) were directly injected by autosampler
(Eksigent nanoLC 425 LC system) at 5 µL/min onto a
YMC Triart-C18 column (15 cm, 3 µm, 300 µm i.d.) using
gradient elution (2–40% mobile phase B, followed by wash
at 80% B and re-equilibration) over either 73 (120 min run
time) min (for spectral library construction using data/
information dependent acquisition DDA/ IDA) or 43 min
(60 min run time) for SWATH/DIA (data independent
acquisition) analysis. Mobile phases consisted of A: water
containing 0.1% (v/v) formic acid; B: acetonitrile con-
taining 0.1% (v/v) formic acid. The LC system was
hyphenated to a Sciex TripleTof 5600+ mass spectro-
meter ﬁtted with a Duospray source and 50 µm electrode
suitable for microﬂow proteomic analysis. The IDA
method was run with parameters of: CUR 25; GS1 15;
GS2 0; ISVF 5500; TEM 0. TOFMS mass range of
400–1250 m/z; accumulation time of 250 ms with product
ion scans on the top 30 ions before switching (dynamic
exclusion for 20 s) with rolling collision energy selected.
Product ion accumulation time was set to 50 ms giving a
cycle time of 1.8 s. The SWATH method was run with the
same source parameters as the IDA with a 50ms TOFMS
scan followed by 100 variable SWATH windows (opti-
mized on an IDA dataﬁle of the same samples) of 25 ms
between 100 and 1500 m/z giving a cycle time of 2.6 s.
A spectral library for SWATH data extraction was
constructed using the output from ProteinPilot 5.0 (Sciex)
searching against the Swissprot Human database (January
2015) with the addition of iRT peptides to the. fasta ﬁle,
combining eight IDA runs (pooled samples) and ﬁltered
and aligned to spike in iRT peptides (Biognosys, Switzer-
land) using PeakView 2.1 (Sciex). SWATH data extraction,
quantitation, and fold change analysis were carried out
using Sciex’s OneOmics cloud processing software suite
incorporating processing methodology from ref. 47. Pro-
teins were considered as differentially expressed if they had
quantitative data on more than a single peptide, with a
OneOmics conﬁdence threshold of 70%.
In vivo experiments
Twenty Foxn1nu nude male mice (6–8 weeks old) were
purchased from the Harlan, Italy (Sanpietro al Natisone).
The mice were maintained under pathogen-free condi-
tions with food and water ad libitum, on 12/12 h day/night
cycle, a temperature of 20 ± 2 °C, ten mice per cage ran-
domized according to weight and tumor burden and
divided in two treatment groups respectively; control
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vehicle (ethanol 100%) and polydatin 100 mg/kg i.p.
UMSCC103 cells were trypsinized, centrifuged, and then
resuspended in serum-free medium. For implantation,
tumor cells were orthotopically inoculated into the right
lateral portion of the tongue of mice (1 × 106 cells per
mouse) using a syringe with a 30 gauge disposable needle
(BD Biosciences). Animals were anesthetized with intra-
peritoneal injections of zolazepam, atropine and xilazine.
From 10 days post injection, mice were treated three
times a week with either control vehicle or polydatin 100
mg/kg via i.p. Tumor growth was assessed every 3 days,
and cervical lymph node metastasis were evaluated with
Ultrasound System Vevo 2100 (Visualsonics, Canada) at
10 and 20 days post cell injection. For each group the area
of the cervical lymph node was assessed with the Vevo
2100 commercial software. At the end of the experiment
(30 days of treatments), mice were killed by CO2 inhala-
tion, dissected, and the tongue and cervical lymph nodes
weighed and photographed. The experimental protocols
were in compliance with the European Community
Council directive (86/609/EEC).
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